On review of the data for these patients from the TCGA paper via cBioportal, we found that amongst esophageal or probable esophageal adenocarcinomas, 76.4% (55/72) had somatic pathogenic variants in TP53, with decreasing prevalence in the indeterminate GEJ (22/36, 61.1%), gastric/probable gastric GEJ (29/63, 46.0%) and gastric non-cardia (113/283, 39.9%) adenocarcinoma groups (Fig. 2). Here, TP53 is linked to gastric neoplasm.